Windtree Therapeutics, Inc. has reached an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC, a private investment group based in the United States. This move allows Windtree to relinquish the financial burden and risks associated with further development while retaining a significant economic interest in the assets’ future success.
Under the terms of the agreement, Seismic will take over the cardiovascular portfolio and will be responsible for ongoing development. Windtree will receive 20 percent of any future milestone payments, royalties, or similar economic benefits generated from these assets. This includes a share of the global commercial net revenues if the drugs receive approval and reach the market.
In addition to the revenue-sharing arrangement, the deal involves a contingent cash payment. Should Seismic complete a financing round that raises at least $10,000,000 in gross proceeds for development, Windtree will receive $700,000. Furthermore, Windtree will transfer certain development-related payables to Seismic, alleviating its near-term financial obligations.
Jed Latkin, Chief Executive Officer of Windtree, emphasized that this agreement enables the company to move away from the costs and risks of further development. He stated, “The structure provides non-dilutive potential value through future proceeds and relieves Windtree of the need to fund continued work on the assets.”
The drugs in question target acute heart failure, a condition responsible for millions of hospital admissions annually. Windtree estimates that there were approximately 2.1 million hospitalizations in the United States and 2.7 million in the European Union in 2022. The company believes the global market opportunity for effective treatments in this area could be worth billions, given the large patient population and the absence of transformative therapies.
This transaction marks a strategic shift for Windtree as it seeks to monetize its past research while improving its financial position. For Seismic Pharmaceutical Holdings, acquiring these assets presents a chance to advance cardiovascular treatments in a field characterized by significant unmet medical needs. Should these programs succeed, Windtree stands to benefit from its retained stake.
As the healthcare landscape evolves, this deal highlights the increasing collaboration between established companies and investment groups, aiming to fast-track development in critical therapeutic areas.
